QUOTE AND NEWS
StreetInsider.com  Sep 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OPKO+Health+%28OPK%29+Data+on+MOD-4023+to+be+Presented+at+ESPE/9824950.html for the full story.
DailyFinance  Sep 8  Comment 
OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an ...
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OPKO+Health+%28OPK%29+Reports+Submission+of+Oral+Rolapitant+NDA+%28TSRO%29/9813747.html for the full story.
SeekingAlpha  Aug 12  Comment 
OPKO Health, Inc. (NYSE:OPK) Q2 2014 Earnings Conference Call August 12, 2014 8:30 am ET Executives Steven D. Rubin - EVP, Administration Phillip Frost - Chairman and CEO Charles W. Bishop - CEO of OPKO Renal Division Scott Toner...
StreetInsider.com  Aug 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OPKO+Health+%28OPK%29+Reports+Positive+Top+Line+Results+from+Rayaldee+Phase+3+Trial/9741522.html for the full story.
StreetInsider.com  Aug 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OPKO+Health+%28OPK%29+Submits+IND+for+Rayaldee/9732582.html for the full story.
StreetInsider.com  Jul 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OPKO+Health+%28OPK%29+Receives+U.S.+Patent+Covering+RAYALDEE/9679146.html for the full story.
StreetInsider.com  Jun 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Opko+Health+%28OPK%29+Granted+Patent+from+European+Patent+Office+for+Lagova/9619616.html for the full story.
StreetInsider.com  Jun 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Opko+Health+%28OPK%29+Reports+No+Statistically+Significant+Data+Observed+in+Lagova+Phase+2+as+Pediatric+GHD+Treatment/9613634.html for the full story.
Benzinga  Jun 25  Comment 
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company, yesterday hosted a webcast presenting outstanding interim six-month results from a Phase 2 study of its long-acting human growth hormone product Lagova to...





You may also be interested in articles related to Opko Health Inc (OPK):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki